BHCM
SYRE icon

Brevan Howard Capital Management’s Spyre Therapeutics SYRE Stock Holding History

Brevan Howard Capital Management’s Portfolio SYRE Stock Details SYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$736K Buy
+8,288
New +$605K 0.01% 1234
2026
Q1 		– Sell
-6,198
Closed -$203K – 2476
2025
Q4 		$203K Buy
+6,198
New +$162K ﹤0.01% 1578
2025
Q1 		– Sell
-16,899
Closed -$393K – 1449
2024
Q4 		$393K Buy
+16,899
New +$496K ﹤0.01% 699

Other funds holding SYRE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Brevan Howard Capital Management's SYRE Position: Q2 2026 in Review

Brevan Howard Capital Management opened a new position in Spyre Therapeutics (SYRE) in Q2 2026: 8,288 shares worth $736K. The stake represents 0.01% of the portfolio and ranks #1234 among its holdings. This is a return to the name: Brevan Howard Capital Management previously reported a position in SYRE as recently as Q4 2025.

Brevan Howard Capital Management first reported a position in SYRE in Q4 2024 and has held it in 3 quarters since. 265 funds tracked by Wall St. Rank hold SYRE as of Q2 2026.

  • Brevan Howard Capital Management held 8,288 shares of Spyre Therapeutics worth $736K as of Q2 2026.
  • Spyre Therapeutics was a new Brevan Howard Capital Management position in Q2 2026.
  • Spyre Therapeutics made up 0.01% of Brevan Howard Capital Management's portfolio in Q2 2026, its #1234 holding.
  • Brevan Howard Capital Management first reported a position in Spyre Therapeutics in Q4 2024 and has held it in 3 quarters since.
  • 265 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q2 2026.

Based on Brevan Howard Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.